Changes to the DSM-5, the updated manual of psychiatric illnesses released earlier this month, include 15 new disorders. The Wall Street Journal’s Jen Wieczner looks at how these new disorders could spell new market opportunities for Big Pharma.
If there was a pill to make you smarter would you take it? A new generation of so-called “smart” drugs is being used by people looking for an edge, but doctors warn of serious potential side effects. Dr. Jeffrey Lieberman of Columbia University Medical Center offers his perspective.
Obesity surgery worked much better at reducing and even reversing diabetes than medication and lifestyle changes in one of the most rigorous studies of its kind. But the researchers and others warn that possible serious complications need to be considered.
One of Vivus Inc.'s biggest stockholders is asking shareholders to vote for its slate of board nominees, continuing its push for new leadership at the company. First Manhattan has criticized Vivus for the failed launch of weight loss drug Qsymia. The Food and Drug Administration approved Qsymia in July, and Vivus started selling the drug in September.
Shares of Rigel Therapeutics Inc. fell to an all-time low Tuesday after its partner AstraZeneca decided not to file for marketing approval of fostamatinib, a rheumatoid arthritis drug Rigel developed. AstraZeneca said earlier studies of fostamatinib were promising, but the company reported results from late-stage studies Tuesday and said they did not measure up.
Elan Corp.'s fight against a takeover bid by Royalty Pharma has spilled into U.S. federal court, where a judge has issued a temporary restraining order preventing Royalty from completing its offer to buy the Irish drugmaker. Royalty is a privately held New York company that buys royalty interests in drugs and late-stage drug candidates. It made an offer to buy Elan last month for $12.50 per share, or about $7.5 billion.
Bayer AG has acquired a majority stake in birth control maker Conceptus Inc. and expects its $1.1 billion purchase of the California company to be completed soon. Bayer said Wednesday that more than 96 percent of the company's outstanding shares were validly tendered and not withdrawn during an offer period that expired Tuesday.
Bristol-Myers Squibb Co. and AstraZeneca PLC said Tuesday the Food and Drug Administration will conduct an accelerated review of their lipid disorder drug metreleptin. The companies want to market metreleptin as a treatment for metabolic disorders associated with rare forms of a condition called...
The widely used C8 phase delivers optimum retention for the analysis of hydrophobic and "sticky" compounds. In combination with Kinetex core-shell technology, this phase gives analysts an excellent high-performance reversed phase alternative for HPLC methods.
Johnson & Johnson is conducting a voluntary recall of millions of oral contraceptive packages in 43 countries outside the U.S., but says there's a "very low" risk that the flawed tablets could cause unplanned pregnancies. The birth control pills are being recalled — but only from pharmacies...
The MX™ Vibro-Energy® round separator has a totally enclosed weight guard that prevents "reach-in" injuries. Making use of the appropriate motor, the MX also complies with ATEX Standards 94/9/EC. The open base construction allows for cleaning underneath the unit, preventing dirt and product build-up to occur.
Treatment for muscular dystrophy, which typically kills patients by their thirties, has not advanced much since the 1980’s. Wall Street Journal reporter Jonathon Rockoff talks about a new generation of drugs that promises to extend patient’s lives by years or decades.
As more adults use prescription drugs, the rate of children being poisoned by them has also dramatically increased. This report details how one family with two young daughters makes sure their prescription drugs stay out of their hands to prevent accidental poisoning.
Renaissance Acquisition Holdings, LLC, a RoundTable Healthcare Partners portfolio company, and GlaxoSmithKline announced today that they have entered into an agreement giving Renaissance the rights in the USA to manufacture, market and sell six dermatology and three anti-viral products from GSK.
Maxygen said it will distribute $68.2 million to $69.6 million, or $2.45 to $2.50 per share, to its shareholders if they approve the liquidation. The company also said James Sulat will resign as CEO and chief financial officer on June 30, and company Chairman Isaac Stein will become its acting CEO and CFO.